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Acute Promyelocytic Leukemia as a Possible Source for Ajulemic Acid Binding
Brian Christopher Monk

Abstract
Acute pro myelocytic leukemia (APL) is a cancer that affects bone marrow,
the blood-forming tissue (of the body) . This type of leukemia accounts for
approximately 10% of acute myeloid leukemia (AML) cases. Normally this cancer is
treated with a drug called all-trans retinoic acid (ATRA), but other variations of
treatment do exist. The importance of this research is that APL cells express
contains a receptor, retinoic acid receptor-a (RARa), which ajulemic acid (AJA) may
bind to in order to induce apoptosis in Ewing sarcoma (ES), a pediatric bone cancer.
Therefore, this research will focus on the ability of AJA to induce the differentiation
of APL cells, as ATRA does, thus demonstrating that AJA may be binding to RARa.
Introduction

Acute Promyelocytic Leukemia
APL is a type of cancer that affects the bone marrow. Normally, bone marrow
produces cells known as hematopoietic stem cells, which give rise to a variety of
different cells within the body. Some of the cells produced include: red blood cells
(erythrocytes), white blood cells (leukocytes), and cell fragments called platelets
(thrombocytes) (Collins, 2002). However, in patients with APL, stem cells are not
able to differentiate, or become specialized into mature functional white blood cells.
Instead, immature white blood cells (WBC) accumulate within the bone marrow.
This results in a shortage of a normal amount of erythrocytes, leukocytes, and
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thrombocytes within the body. Figure 1 shows the pathway that a hematopoietic
stem cell takes to reach one of its three outcomes: erythrocyte, leukocyte, or
thrombocyte.
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Figure 1: The image above shows the normal route of a hematopoietic stem
cell takes to become a red blood cell (RBC), platelet, or WBC.
From: The National Cancer Institute "What You Need to Know About
Leukemia."
In patients with APL, the problem arises in a cell called a
promyelocyte. Promyelocytes are derived from myeloblasts and eventually give
way to granulocytes. These then go on to produce neutrophils, eosinophils,
basophils, and mast cells (Figure 2). In APL the promyelocytes are unable to
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differentiate into these different types ofWBCs and cause blockage within the
marrow, leading to the overall effect of fewer RBC, WBC, and platelets.

Figure 2: Promyelocytes that differentiate into different WBC. (Left to right:
neutrophil, monocyte, basophil, lymphocyte, and eosinophil).
From: The University of California at San Francisco, Science & Health
Education.

APL accounts for approximately 10% of all acute myeloid leukemia (AML),
and occurs in 1 out of every 250,000 people in the United States (Yamamoto, et al.,
2007). With that, it accounts for 21,700 deaths per year and has a higher incidence
rate within the Hispanic community. The average APL patient is diagnosed around
age 40, but can be diagnosed at any age.
APL is caused by a translocation of two chromosomes: 15 and 17 (The,
1991). Normally on chromosome 15, the PML gene, produces a protein that acts as
a tumor suppressor (Salomoni, et al., 2002). This protein is able to prevent cells
from growing and replicating too rapidly within the body. Chromosome 17,
containing the RARa gene, produces a protein that helps regulate gene transcription
(the first step in the formation of protein production) (The, et al., 1991). This
protein controls genes in WBC differentiation beyond the promyelocye stage. With
patients that have APL, 98% of the cases are due to the translocation, or fusion, of
both chromosomes 15 and 17 (Zelent, et al., 2001). The fusion of these

chromosomes produces a gene called PML-RARa. This gene interferes with both the

normal processes of chromosomes 15 and 17. It does so by producing cells that are
caught in the promyeloctye stage, leading to abnormal differentiation and
accumulation. Ultimately this does not allow for the formation of mature and
functional WBC. Interestingly enough, APL is not a genetic disease (Zelent, et al.,
2001). It is acquired throughout one's lifetime and is only present in certain cells.

This specific type of mutation is called a somatic mutation.
Diagnosis of this disease is done through observation of signs and symptoms,
as well as diagnostic procedures. Normal symptoms that are observed in patients
with APL are: fatigue, weakness, anemia (low RBC), bruising, bleeding, fever, and
infection (Sanz, et al., 2010). In a proper diagnosis, a doctor would note all signs and
symptoms of the patients, and order certain tests. These test check the patient's
complete blood count (CBC), electrolyte levels, prothrombin time (PT) (blood test to
measure how long it requires blood to clot), and activated partial thromboplastin
time (aPPT) (blood test that characterizes blood coagulation). In addition, a bone
marrow biopsy would be done to test for the presence of abnormal WBC.
There are many different treatment options for patients with APL; the
normal treatment being all-trans-retinoic acid (ATRA) in combination with a
chemotherapeutic anthracycline drug (daunorubicin or idarubicin) (Attar, et al.,
2013). ATRA helps promyelocytes differentiate into functioning neutrophils,

reduces the total number of leukemic cells within the bone marrow, and aids in
reducing the side effects of chemotherapy. For patients who cannot handle the use
of anthracycline drugs or who relapse, ATRA with arsenic trioxide (As03) is
prescribed (Gore, et al., 2010). Overall, 80% of patients achieve short-term

remission when treated with ATRA alone and 70-80% achieve remission when
treated with the combination of both ATRA and an anthracycline (The Leukemia and
Lymphoma Society.). Those who achieve remission must undergo long-term followups to ensure they are cured of the disease and determine if additional therapy is
required. Therapy in order to maintain remission consists of treatment with 6mercaptopurine (6-MP), methotrexate, and ATRA for at least two years (Gore,
2010).

Ewing's Sarcoma

Ewing's sarcoma (ES) is a cancer that occurs in either bones or soft tissues.
There are several different types of ES, each affecting a different part of the body
(Bailly, et al., 1994). Besides ES of the bone, there is extra osseous ES, which are
tumors that occur in the soft tissues that surround the bone (i.e. cartilage).
Peripheral primitive neuroectodermal tumors (pPNET) occur within nerve tissues.
Askin tumors, a subtype of pPNET, are located within the chest.
Out of all these different types of ES, 87% occur in the bones. Figure 3 shows
the areas of the body that are affected (Sankar, eta!., 2011). Common cases ofES
occur in the femur (thigh), pelvis, or humorous (arm). Abnormal cases would
consist of ES affecting the ribs, spine, etc. It is very common that ES will metastasize
to another part of the body. Lungs, other bones, or marrow, are typical places to see
the cancer spread.
ES affects approximately 3 out of 1 million children each year (Sankar, eta!.,
2011). In the United States, 250,000 are diagnosed with some form of ES each year,
making it the second most common form of bone cancer. ES tends to affect children

and young adults who are between the ages of 10 and 20. Affecting more boys than
girls, and rarely occurring in either African-Americans or Asian Americans, ES
accounts for 1.5% of all pediatric cancers that are diagnosed.
Like APL, Ewing's sarcoma is not inherited genetically, making it a somatic
mutation. ES arises from the translocation of two genes EWSR1 on chromosome 22
and FLil on chromosome 11 (May, 1993). When parts of these two genes fuse
together, they create the EWSR1/FLI1 gene. This gene is what leads to the
development of ES. Normally, the FLI1 protein helps regulate transcription as well
as binding to DNA (May, 1993). The protein then helps control the overall
development of certain cells by controlling the rate of transcription of certain genes.
Regulating transcription is also the major function of the EWSR1 protein, under
normal conditions (Mao, et al., 1994). However, when the two genes fuse together,
the new protein turns transcription on or off on a variety of different genes,
ultimately leading to abnormal differentiation and growth of cells. In patients
diagnosed with ES, 85% of them have the ESWR1/FLI1 mutation.
Diagnosis of this cancer is done through both observations of signs and
symptoms, as well as diagnostic procedures. Normal signs and symptoms that are
apparent in patients withES are: edema (swelling) or soreness around the area of
the tumor, a low-grade fever, bone pain that specifically intensifies during exercise
or while sleeping, and limping caused by the tumor being present on the bone (St.
Jude). Using diagnostic procedures, a physician would use not only a physical exam,
but also an MRI, CT, bone scan, bone marrow biopsy, or the use of PCR for the
EWSR1/FLI1 gene, to help make a definitive diagnosis of ES. Typical treatment for
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ES includes chemotherapy, surgery (possibly amputation to guarantee that all the
cancer is removed) and radiation (St. Jude). The overall survival rate for children
withES is 70%, however that number drastically decreases to 30% for 5-year
survival rate.

Figure 3: Image depicting occurrences of Ewing's Sarcoma (ES) within the
body.
From: Dr. Frank Gaillard, et a!.

Cannabinoids
Cannabinoids have been used for recreational purposes for sometime now.
However, these recreational drugs are being studied for their potency on cancer.
Research defines a cannabinoid by its ability to bind to either CB1 or CBz (Figure 4).
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The CB1 receptor is found throughout the body in places such as the brain, spleen,
eye, testis, and uterus (Cridge, et al., 2013). CBz on the other hand, is found on cells
that deal with the immune system as well as tumor cells. These receptors belong to
a specific type of protein receptors called G-protein coupled receptors, whose
purpose is to transduct signals from outside the cell. The CB1 receptor mediates
psychotropic effects of cannanibinoids (Cridge, et al., 2013). On the opposite side,
CBz functions in moderating the immune system's effect (Cridge, et al., 2013).
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Figure 4: Image shows the two cannabinoid receptors (CB1 and CBz) and
their physical shapes.
From: pubs.rsc.org
Research showing that cannabinoids do in fact inhibit tumor growth is
extensive. A specific cannabinoid-.1 8 - THC (tetrahydrocannabinol)-was used on mice
with lung cancer. Researchers found that after twenty days of treatment, the drug
inhibited growth of the tumor. Ceramides were found to be very prominent when
either CB1 or CBz were activated (Cridge, et al., 2013). Ceramides are very
important in physiological signaling, controling events such as apoptosis (cell
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death), growth arrest (certain stage within the cell cycle), differentiation of cells, cell
migration and adhesion. When either CB1 or CBz were activated, researchers saw an
increase in ceramide levels, which led to apoptosis or cell cycle arrest within tumor
cells. Cannabinoids were found to prevent angiogensis (the formation of new blood
vessels). This is a critical necessity for tumors in order to develop and when
undergoing treatment with cannabinoids, researchers found decreased angiogenic
activity (Cridge, et al., 2013) .
Although there are many derivatives of cannabinoids that are undergoing
further studies to test for efficacy on cancer, our research focused on ajulemic acid
(AJA). AJA (CzsH 3604), shown in Figure 5, is a crystalline solid at room temperature
and has shown to inhibit psychotropic effects when administered (Burstein, 2004).
This makes it a very good treatment for Ewing's sarcoma because children won't
experience the high that is associated with normal cannabis plants. The drug has
shown to bind effectively to both the cannibinoid receptors (Burstein, et al., 2013).

<·uun

Figure 5: Ajulemic Acid (AJA) (CzsH3604, MW= 400.55 gjmol) shows
excellent capabilities in the treatment of cancers, especially Ewing's sarcoma.
From: Sumner Burstein"Ajulemic Acid {IP-751): Synthesis, Proof of Principle,
Toxicity Studies, and Clinical Trials", 2004
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Relevance of Study
The purpose of this study is to test a possible receptor to which AJA may be
binding. Previous research has indicated that AJA binds to a certain receptor called
peroxisome proliferator-activated receptor gamma (PPAR-y) (Liu, 2003). When ES
cells were tested in the lab for the expression ofthis receptor via Western blot,
PPAR-y was not expressed. Therefore, it was concluded that AJA was binding to
another receptor. Studies done from previous research found possible candidates
for A} A's binding site. The RARa and vitamin D receptors were among some of the
strongest candidates. This particular research was to focus on the RARa receptor.
By using APL cells, which not only express the RARa receptor, but ligand-binding to
this receptor can be easily monitored by assessing the differentiation of APL cells.
This experimental model was perfect to see if AJA binds to RARa.
Several other drugs were tested alongside AJA. ATRA was used as a positive
control in order to compare the efficacy of the two drugs. Other drugs, 9 cis-retinoic
acid (cis-RA), cannabidiol (CBD), and hemp oil, were used to test the efficacy on APL.
Hemp oil and CBD were used to test other derivatives from the cannabis plant.
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Materials
Ajulemic Acid (A]A)
AJA, dimethylheptyl-THC-11-oic acid, was prepared in dimethyl sulfoxide

(DMSO) to a final stock concentration of 10 mM.

All- Trans Retinoic Acid (ATRA)
ATRA, was prepared in ethanol to a final stock concentration of0.01 mM and

1mM.

9 Cis-Retinoic Acid (cis-RAJ
Cis-RA, was prepared in DMSO to a final stock concentration of 0.1 mM.

Hemp Oil
Hemp oil, was prepared in DMSO to a final stock concentration of 0.1 mM and
l!JM .

Cannabidiol (CBD)
CBD, was prepared in ethanol to a final stock concentration of 0.1 mM and 1

mM.

Cell Culture
HL-60 cells (leukemic cells from an APL patient) were grown in suspension
in IMDM media (20% fetal bovine serum (FBS) with penicillin and streptomycin)
and cultured at 37°C with 5% COz.
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Methods

Maintenance of Cell Line
Cells were maintained to produce enough viable cells in order to test the
efficacy of different treatment options. One of the main indicators of cell line
maintenance was a foggy, milky color being present. If present, this allowed us to
properly spilt the HL-60 cells (place old cells into a new flask with fresh media and
providing new media for the original flask as well). This process was repeated
throughout the experiment. Another indicator we used was a microscope. When
viewing the cells, if there were a lot of dead cells in the flask, this was an indicator
that they too needed to be split.
NBTAssay

The efficacy of treatment of AJA on APL cells was done via NBT (nitro blue
tetrazolium) assay composed of two tetrazole moieties (5-membered ring with 4
nitrogen's and 1 carbon). The NBT assay procedure was prepared by first spinning
down cells in the centrifuge and vacuuming off media. Cells were suspended in 1
mL of NBT /PMA (composition of solution) that was warmed before submersion of
cells. Cells were then placed into the incubator for 30 minutes at 37°C. After the 30
minutes, 83

~L

of HCl was added to the cells. The addition of HCl stops the reaction

of the NBT /PMA with APL cells. Cells were then spun down and liquid was
vacuumed off. Cells were then suspended in 0.5 mL of DMSO; which caused a purple
color to form. The cells plus DMSO were moved to a well plate in order to be read
by the TECAN Infinite Series at 560 nm. The machine measured absorbency by
measuring the light that was absorbed. The effectiveness of treatment is indicated
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by the shade of purple produced from the assay. Thus the darker the shade of color,
the more effective and vice versa. Results were drafted and saved.
The NBT assay tests for oxidative free radicals produced by WBCs. In
patients who do not suffer from APL, pathogens that are recognized are targeted
with oxidative radicals produced from the WBCs. In patients with APL, this process
does not occur. Thus, the darker shade of purple produced from the assay tells us
that AJA caused the cells to differentiate into normal WBCs. The lighter the color,
the less effective the drug was on APL cells.
The NBT assay was performed with all drugs used to test for the
differentiation of APL cells.

Results
APL Treatment with ATRA

To establish a positive control, we first tested ATRA on APL cells. ATRA is
the normal treatment for APL; therefore we would have a positive baseline for AJA
when it underwent testing. HL-60 cells were grown and cultured, in order to get a
sufficient amount to treat. Cells were either untreated (UT) or treated with ATRA
(30 nM). The amount of cells needed for treatment was calculated and found to be
1x10 4 cellsjmL. The average amount of cells in each flask (2 UT and 2 ATRA) were
calculated via hemocytometer. The following results were obtained:
Untreated APL
Cells
A

B

Average Number of
Cell for UT
(cellsjmL)
272x10 4
198.5x10 4

ATRA APL Cells
A
B

Average Number of
Cells for ATRA
(cellsjmL)
159x10 4
207.5x104

1~

Following total cell count of the both UT and ATRA cells, NBT assay was
performed on both groups. Figure 6 shows the results obtained from the
experiment.

HL-60 NBT Assay
30nM ATRA, 7 days
10-21-14
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Figure 6: Results showing the absorbance of 560nm for UT APL cells and
ATRA treated APL cells.

APL Treatment with ATRA & A]A
Having established a positive control for the experiment, comparing ATRA vs.
AJA was next. Cell lines from the previous experiment were continuously grown

and cultured. Cells were divided into three categories of treatment: UT, ATRA (30
nM), or AJA (30 nM). The amount of cells needed for treatment was calculated and
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found to be 1x10 7 cells/mL. The average number of cells was calculated via
hemocytometer. The following results were obtained.

Untreated
APL Cells

A
B

Average
Number of
Cells for UT
(cells/mL)
313 .5x10 4
303x10 4

ATRAAPL
Cells

A
B

Average
Number of
Cells for
ATRA
(cells/mL)
303x10 4
201x10 4

AJAAPL
Cells

A
B

Average
Number of
Cells for
AJA
(cells/mL)
221.5x104
207x10 4

Following total cell count for UT, ATRA, and AJA, NBT assay was performed
on all three trials. Figure 7 shows the results obtained from the exper

H L-60 Treatment with AJA and
ATRA 10/29/14
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Figure 7: Results showing differentiation between APL UT, AJA, and ATRA
(**p-value<.OS).
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APL Treatment with ATRA and Varying Concentrations ofA]A
Evaluating the results shown in Figure 7, we decided to vary the
concentration of AJA, to see if a higher molar concentration induced differentiation.
Using the stock concentration of AJA we calculated the different molar
concentrations (M1V1=MzVz). Cell lines were continuously grown and cultured.
Upon treatment, cells were divided into five categories: UT, ATRA (30 nM), AJA (30
nM), AJA (300 nM), and AJA (3 11M). The amount of cells needed for treatment was
calculated and found to be 1x10 7 cells/mL. The average number of cells was
calculated via hemocytometer. The following results were obtained.

Untreated
APL Cells

A
B

Average
Number
of Cells
forUT
(cellsjmL)

ATRA
APL
Cells

Average
Number
of Cells
for ATRA
(cells/mL)

AJA
APL
Cells
(30
nM)

237x104
196xl04

A
B

233x104
214x104

A
B

Average
Number
of Cells
for APL
(30 nM)
(cells/mL)
212x104
207xl04

AJA
APL
Cells
(300
nM)
A
B

Average
Number
of Cells
for APL
(300 nM)
(cells/mL)
244x104
241x104

AJA
APL
Cells
(3
!lM)
A
B

Average
Number
of Cells
for APL (3
!lM)
(cells/mL)
237x104
213x104

Following total cell count for UT, ATRA, AJA (30 nM), AJA (300 nM), and AJA
AJA (3 11M), NBT assay was performed on all five trials. Figure 8 shows the results
obtained from the experiment.
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HL-60 Treatment With Varying Concentrations of AJA
11/11/14
0.45
E 0.40
s:::::
0.35
0
e.g
It)
0.30
Cl)
(.)
0.25
s:::::
ra 0.20
.c
"'- 0.15
0
f/)
.c 0.10
<(
0.05
0.00

Figure 8: Results showing the differentiation between APL UT, ATRA, AJA
(30 nM), AJA (300 nM), and AJA AJA (311M).

APL Treatment with ATRA, A]A, CBD, and Hemp Oil

The final experiment was to test different cannabinoids on the differentiation
of APL cells. Cells were continuously grown and cultured before the experiment.
Using the stock concentrations of the different drugs, we calculated the different
molar concentrations (M1 V1=MzVz). Upon treatment, cells were divided into nine
catagories: UT, ATRA (30 nM), cis-RA (30 nM), AJA (30 nM), AJA (311M), CBD (30
nM), CBD (3 11M), Hemp oil (30 nM), and Hemp oil (3 11M). The total number of cells
needed for treatment was calculated and found to be 1x10 7 cellsjmL. The average
number of cells was calculated via hemocytometer. The following results were
obtained.
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Average
Number of
Cells for UT
(cellsjmL)

Untreated
APL Cells

4x10 7
4.7x107

A

B

AJAAPL
Cells (3
1-!M)

A
B

ATRAAPL
Cells

Average
Number of
Cells for
AJA(3
1-!M)
(cells/mL)

A

B

CBDAPL
Cells(30
nM)

3.2x107
3.3x107

A
B

Average
Number of
Cells for
CBD (30
nM)
(cells.mL)

3.2x10 7
3.2xl0 7

Average
Number of
Cells for
ATRA
(cellsjmL)

Cis-RAAPL
Cells (30
nM)

Average
Number of
Cells for cisRA (30 nM)
( cellsjmL)

AJAAPL
Cells (30
nM)

Average
Number of
Cells for AJA
(30 nM)
(cellsjmL)

4.5x10 7
4 Sx107

A

4.3x10 7
4.3x107

A

3.2x107
3.6x107

CBD APL
Cells(3
1-!M)

A
B

B

Average
Number of
APL Cells
for CBD (3
1-!M)
(cells/mL)

Hemp Oil
APL Cells
(30 nM)

4x10 7
3.3x10 7

A
B

B

Average
Number of
Cells for
Hemp Oil
(30 nM)
(cells/mL)

4.3x107
3.5x10 7

Hemp Oil
APL Cells
(31-!M)

Average
Number of
Cells for
Hemp Oil
(31-!M)
(cells/mL)

3.7xl0 7
4.3x10 7

A
B

Following total cell count for UT, ATRA, cis-RA, AJA (30 nM), AJA (3 ~M), CBD
(30 nM), CBD (3

~M),

Hemp oil (30 nM), and Hemp oil (3

~M),

NBT assays were

performed on all nine trials. Figure 9 below show s the results obtained from the

experiment

18

HL-60 Treatment 11/24/14
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Figure 9: Results showing the differentiation between APL UT, ATRA, cis-RA,
AJA (30 nM), AJA (3 ~-tM), CBD (30 nM), CBD (3 ~-tM), Hemp oil (30 nM), and
Hemp oil (3 ~-tM) .
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Discussion
The use of cannabinoids as a possible source for medical treatments has
received a lot of attention. Large amounts of research have been focusing on how
these drugs help treat diseases such as cancer. One of these cannabinoids, AJA, has
been studied extensively because it elicits no psychotropic effects when compared
tetrahydrocannabinol (a compound from the marijuana plant that causes
psychotropic effects). This research focused on using APL cells to help determine
the possible receptor that AJA may be binding to when treating Ewing's sarcoma
cells.
APL cells (HL-60) underwent various forms of treatment throughout the
experiment. Having the positive results from ATRA helped show the possible
outcome if AJA did indeed bind to RAR-a. However, once the APL cells underwent
treatment with AJA, there was little differentiation observed. Figure 10 shows the
difference between normal WBC and abnormal WBC found in APL patients. The
following figure is to show the desired affect of the drug, providing it did in fact bind
to RAR-a.

7()

Figure 10: WBC observed in patients with APL (left) and WBC observed in
healthy patients. The distinguishing difference between the two images in
APL the nuclei of the cells are hard to distinguish (left) compared to those
without APL (right). Therefore, if AJA did in fact bind to RAR-a, APL cells
(left) would differentiate to normal WBC (right).
From: American Society of Hematology Image Bank, Luhan Swart, Ann van
Eyssen, Margie Shuttleworth (left) and Atlas Genetics Oncology (right)
However, when APL cells underwent treatment with AJA, little or no
differentiation was observed. Figure 11 shows the images taken from the lab with
the various treatments (UT, ATRA (30 nM), and AJA (30 nM)). Even increasing the
concentrations of AJA did not cause the APL cells to differentiate. Other sources of
cannabinoids, such as CBD or Hemp oil, had the same results as AJA, little or no
differentiation. Therefore, with these results, we believe that AJA does in fact bind
to RARa in APL cells, however at a very low affinity. This suggests that AJA may be
binding to more than one receptor. Further research is needed to test the other
possible receptors that AJA may be binding to.

?1
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Figure 11: The top left image is APL cells UT, top right image is APL cells treated
with 30 nM of ATRA, and the bottom left image is APL cells treated with 30 nM of
AJA. There is clear evidence that AJA does induce some differentiation of APL cells,
however a majority are still promyelocytes.
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